- €1.32bn
- €1.21bn
- €174.86m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 24.21 | ||
| PEG Ratio (f) | 0.6 | ||
| EPS Growth (f) | 67.79% | ||
| Dividend Yield (f) | 0.87% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.32 | ||
| Price to Tang. Book | 6.35 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.53 | ||
| EV to EBITDA | 91.67 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.42% | ||
| Return on Equity | 13% | ||
| Operating Margin | 3.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 269.96 | 229.83 | 196.34 | 158.15 | 174.85 | 176.85 | 219.02 | 15.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -31.95 | -45.33 | -97.61 | +2097.06 | +85.12 | +45.8 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
Directors
- Jose Maria Fernandez Sousa-Faro CHM
- Pedro Francisco Fernandez Puentes VCH
- Maria Luisa de Francia Caballero CFO
- Jose Maria Jimeno VPR
- Carmen Cuevas Marchante VRD
- Heiner Pieper VBD
- Juan Gomez Pulido GCN
- Luis Mora Capitan MDR
- Juan Nogues Ortuno DSL
- Jose Luis Moreno Martinez-Losa DIR
- Maria Jose Arce-Tomas OTH
- Pascal Besman OTH
- Elisa Borrego OTH
- Elena Calleja Crespo OTH
- Carmen Eibe Guijarro OTH
- Sandra Llamera Sanchez OTH
- Jose Luis Ortega Conejero OTH
- Alfonso Ortin OTH
- Maria Sanz OTH
- Belen Sopesen Veramendi OTH
- Juan Carlos Villalon Gomez OTH
- Ali Zeaiter OTH
- Carlos Pazos Campos LED
- Montserrat Andrade Detrell DRC
- Maria Sandra Ortega Mera DRC
- Jose Felix Perez-Orive Carceller DRC
- Eduardo Serra Rexach DRC (75)
- Valentin de Torres-Solanot del Pino IND (58)
- Maria Blanca Hernandez Rodriguez IND
- Ana Palacio Vallelersundi IND
- Carlos Solchaga Catalan IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 30th, 1986
- Public Since
- November 2nd, 2015
- No. of Employees
- 500
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Madrid Stock Exchange- Shares in Issue
- 17,574,931
- Address
- Avda. De los Reyes, 1, Pol. Ind. La Mina, COLMENAR VIEJO, 28770
- Web
- https://www.pharmamar.com/es/
- Phone
- +34 918466000
- Contact
- Jose Luis Moreno Martinez-Losa
- Auditors
- KPMG Auditores, SL
Latest News for PHM
Upcoming Events for PHM
Q1 2025 Pharma Mar SA Earnings Release
Pharma Mar SA Annual Shareholders Meeting
Q2 2025 Pharma Mar SA Earnings Release
Similar to PHM
Almirall SA
Madrid Stock Exchange
Faes Farma SA
Madrid Stock Exchange
Grifols SA
Madrid Stock Exchange
Natac Natural Ingredients SA
Madrid Stock Exchange
Labiana Health SA
Madrid Stock Exchange
FAQ
As of Today at 22:37 UTC, shares in Pharma Mar SA are trading at €74.95. This share price information is delayed by 15 minutes.
Shares in Pharma Mar SA last closed at €74.95 and the price had moved by +182.62% over the past 365 days. In terms of relative price strength the Pharma Mar SA share price has outperformed the FTSE Global All Cap Index by +177.64% over the past year.
The overall consensus recommendation for Pharma Mar SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePharma Mar SA does not currently pay a dividend.
Pharma Mar SA does not currently pay a dividend.
Pharma Mar SA does not currently pay a dividend.
To buy shares in Pharma Mar SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €74.95, shares in Pharma Mar SA had a market capitalisation of €1.32bn.
Here are the trading details for Pharma Mar SA:
- Country of listing: Spain
- Exchange: MCE
- Ticker Symbol: PHM
Based on an overall assessment of its quality, value and momentum Pharma Mar SA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pharma Mar SA is €89.70. That is 19.68% above the last closing price of €74.95.
Analysts covering Pharma Mar SA currently have a consensus Earnings Per Share (EPS) forecast of €2.72 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharma Mar SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +11.26%.
As of the last closing price of €74.95, shares in Pharma Mar SA were trading +10.63% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pharma Mar SA PE ratio based on its reported earnings over the past 12 months is 24.21. The shares last closed at €74.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pharma Mar SA's management team is headed by:
- Jose Maria Fernandez Sousa-Faro - CHM
- Pedro Francisco Fernandez Puentes - VCH
- Maria Luisa de Francia Caballero - CFO
- Jose Maria Jimeno - VPR
- Carmen Cuevas Marchante - VRD
- Heiner Pieper - VBD
- Juan Gomez Pulido - GCN
- Luis Mora Capitan - MDR
- Juan Nogues Ortuno - DSL
- Jose Luis Moreno Martinez-Losa - DIR
- Maria Jose Arce-Tomas - OTH
- Pascal Besman - OTH
- Elisa Borrego - OTH
- Elena Calleja Crespo - OTH
- Carmen Eibe Guijarro - OTH
- Sandra Llamera Sanchez - OTH
- Jose Luis Ortega Conejero - OTH
- Alfonso Ortin - OTH
- Maria Sanz - OTH
- Belen Sopesen Veramendi - OTH
- Juan Carlos Villalon Gomez - OTH
- Ali Zeaiter - OTH
- Carlos Pazos Campos - LED
- Montserrat Andrade Detrell - DRC
- Maria Sandra Ortega Mera - DRC
- Jose Felix Perez-Orive Carceller - DRC
- Eduardo Serra Rexach - DRC
- Valentin de Torres-Solanot del Pino - IND
- Maria Blanca Hernandez Rodriguez - IND
- Ana Palacio Vallelersundi - IND
- Carlos Solchaga Catalan - IND